Kisspeptin-10 vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
- ~13 hours (once-daily dosing)
- Admin Route
- SubQ, IV
- SubQ
- Research
- —
- —
- Typical Dose
- 50–500 mcg
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once daily to every other day
- Once daily
- Key Benefits
- Potently stimulates LH and testosterone
- Enhances sexual arousal and libido
- Activates HPG axis — upstream of GnRH
- May improve fertility in hypogonadotropic hypogonadism
- Increases brain activation in sexual attraction circuits
- May restore LH pulsatility in suppressed HPG axis
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Injection site reactions
- Temporary nausea
- Flushing
- Elevated LH/testosterone (intended effect)
- +1 more
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —